Positive Initial Ph 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) announced
“We are highly encouraged by the early signs of efficacy from the SLATE immunotherapy program, in particular, from our product candidate targeting multiple KRAS oncogenic mutations in patients with advanced, treatment-refractory disease (SLATE-KRAS),” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone. “We observe molecular responses in approximately 40% of all evaluable subjects receiving SLATE, and those seen in our NSCLC patients are correlating nicely with extended overall survival, which has been described in recent publications with checkpoint inhibitors. This relationship between OS and ctDNA response was also observed in our GRANITE individualized immunotherapy study in patients with advanced CRC, as published recently in Nature Medicine. Patients with NSCLC without a molecular response had a median overall survival of just 4.5 months, underscoring the encouraging efficacy signal with SLATE in this challenging context with high unmet need for alternative treatment options. The clinical and mechanistic observations across our shared and individualized neoantigen vaccine programs is strikingly consistent, as is the favorable safety and tolerability profile, reinforcing the therapeutic potential of our oncology vaccine programs.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines